Product nameAnti-NFYA antibody
See all NFYA primary antibodies
DescriptionRabbit polyclonal to NFYA
Tested applicationsSuitable for: WB, IP, ELISA, EMSAmore details
Species reactivityReacts with: Mouse, Human
NF-Y (A subunit specific) peptide corresponding to a region near the N-terminus of the human protein conjugated to Keyhole Limpet Hemocyanin (KLH).
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 0.88% Sodium chloride, 0.42% Potassium phosphate
Concentration information loading...
Purification notesThis product was prepared from monospecific antiserum by delipidation and defibrination.
Our Abpromise guarantee covers the use of ab6558 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Predicted molecular weight: 39 kDa.|
|IP||Use at an assay dependent dilution.|
|ELISA||Use at an assay dependent dilution.|
|EMSA||Use at an assay dependent dilution.
FunctionStimulates the transcription of various genes by recognizing and binding to a CCAAT motif in promoters, for example in type 1 collagen, albumin and beta-actin genes.
Sequence similaritiesBelongs to the NFYA/HAP2 subunit family.
- Information by UniProt
- CAAT box DNA binding protein subunit A antibody
- CAAT box DNA-binding protein subunit A antibody
- CBF A antibody
Anti-NFYA antibody (ab6558) at 1/500 dilution + CaPan1 whole cell lysate at 50 µg
HRP-conjugated Donkey anti-Rabbit. at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 39 kDa
Observed band size: 39 kDa
Additional bands at: 40 kDa, 50 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 10 minutes
This product has been referenced in:
- Hiramoto M et al. A type 2 diabetes-associated SNP in KCNQ1 (rs163184) modulates the binding activity of the locus for Sp3 and Lsd1/Kdm1a, potentially affecting CDKN1C expression. Int J Mol Med 41:717-728 (2018). WB ; Rat . Read more (PubMed: 29207083) »
- Ma H et al. ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA. Oncotarget 6:1049-63 (2015). IP, ChIP ; Human . Read more (PubMed: 25473899) »